AIVLOSIN® USA & CANADIAN MARKETING AUTHORISATIONS

13 January 2021

ECO Animal Health Group plc

("ECO", "the Company" or the "Group")

(AIM: EAH)

USA AND CANADIAN MARKETING AUTHORISATIONS FOR AIVLOSIN®

ECO Animal Health Group plc is pleased to announce that it has received marketing authorisations from the United States Center for Veterinary Medicine of the Food and Drug Administration and from the Veterinary Drugs Directorate of Health Canada for Aivlosin®.

These approvals of Aivlosin® Water Soluble Granules add Mycoplasma hyopneumoniae to the list of pathogens indicated for the control of swine respiratory disease ("SRD").

M. hyopneumoniae is a primary pathogen in swine respiratory disease complexes playing an important role in facilitating the entry of bacterial and viral pathogens. SRD occurs worldwide and causes major economic losses to the pig industry.

Aivlosin® Water Soluble Granules is under the control of North American veterinarians and is available under prescription only. It has a low, highly effective dose rate, short treatment duration and a zero day drug withholding period. The product will be marketed through Pharmgate Animal Health, the Group's well-established sales and marketing joint operation with Pharmgate Corp (the majority-owned US subsidiary of Jinhe Biotechnology Co., Ltd., P. R. China).

Marc Loomes, CEO said: "We are delighted to receive this significant marketing authorisation for Aivlosin® Water Soluble Granules in the USA and in Canada which are among the most important pork producing and exporting countries in the world. M. hyopneumoniae plays a pivotal role in the important SRD segment and its control is frequently considered by swine producers to be one of the most important issues they face today."

Contacts: 

 Notes:

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

Pharmgate Corp is the majority-owned US subsidiary of Jinhe Biotechnology Co., Ltd., P. R. China, the world leader in the production of chlortetracycline and other fermentation compounds, and more recently, the majority owner of Hangzhou UBEN Animal Vaccine Co., Ltd., a company manufacturing and supplying vaccines to the domestic market in China.

ECO and Pharmgate have jointly established Pharmgate Animal Health in the United States of America (2010) and Canada (2011) where these successful operations market their owners' product portfolios for livestock.

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.